Allergan, SonarMD to develop IBS-D patient engagement platform

Allergan and SonarMD have partnered to develop clinical decision support and patient engagement tools to improve diagnosis and monitoring of patients with diarrhea-predominant irritable bowel syndrome, according to a press release.

The companies will leverage SonarMD’s cloud-based care management platform, which uses “care management algorithms” to enable health care providers to engage, monitor and manage patients between visits through secure ongoing health assessments of symptoms, quality of life and treatment effects, according to the press release. These data can alert physicians to changes in a patient’s condition and potentially improve health outcomes and decrease costs.

“Traditionally, the limited diagnostic and therapeutic options available for patients suffering from irritable bowel syndrome, combined with the reluctance of those patients to discuss their symptoms with health care practitioners, has presented a major barrier to providing them with the most effective care. The collaboration between SonarMD and Allergan is focused on developing tools which will help providers more efficiently identify IBS-D patients, deliver quality care and, simultaneously, foster meaningful patient engagement,” Jonathan Rosenberg, SonarMD’s Medical Director, said in the press release. “I am excited about the potential for this project to generate meaningful patient reported data, which will lead to better care outcomes for all IBS-D sufferers through more effective care delivery from their providers.”

Disclosures: Rosenberg is employed by SonarMD.